The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia

On November 6, 2025, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology ...

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin ...

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated safety and efficacy data from the BEACON ...
TMCnet

BOOST Pharma Adds Sound Bioventures to Investor Syndicate with SEK 34 Million Investment to Advance Stem Cell Therapy for Osteogenesis Imperfecta

BOOST Pharma ApS, a clinical-stage biopharmaceutical company focused on developing novel cell therapies for rare skeletal pediatric diseases, today announced that Sound Bioventures has joined its ...

GM-free coalition disputes ICAR’s claims on performance of new gene-edited rice varieties

The group alleges selective use of field trial results to project higher yields and early maturation while ICAR scientists defend the evaluation process as transparent and scientifically sound ...

Unprecedented Clinical data from the Landmark BOOSTB4 Trial to be presented at the 15th International Conference on Osteogenesis Imperfecta in Hong Kong

The presentation will provide two-year follow-up data from the landmark BOOSTB4 Phase I/II clinical study. Notably, the results demonstrate that more than 50% of the treated patients experienced zero ...
PregaTips on MSN

Fertilisation 101: What's Happening Inside You

If you’re trying to conceive, learning about fertilisation makes the process less of a mystery. It highlights that conception ...